Press Releases

Induced Pluripotent Stem Cells Production Market Estimated to Cross US$ 2.70 Bn by 2030

The global Induced Pluripotent Stem Cells Production market size is expected to reach USD 2.70 billion by 2030 and is expected to expand at a CAGR of 9.0% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38601

Growth Factors

 The market is driven by technological advancements in induced pluripotent cell manufacturing, rising awareness about the therapeutic potency of such cells, and extensive research on the development of  using induced pluripotent cells. The ability of iPS cells to differentiate with maximum diversity has been one of the key drivers propelling its usage in gene and cell therapy applications. The high therapeutic potential of induced pluripotent stem cells (iPSCs) has expanded its applications in the past few years making significant contributions to the market revenue.

The robust pipeline for iPSC-derived cell therapeutics coupled with emerging applications of iPSCs is anticipated to accelerate the market growth. As of 2021, the total number of iPSC clinical trials has risen to 54. For instance, Allele Biotechnology & Pharmaceuticals is developing a diabetics drug from iPSC-derived pancreatic beta cells.

Report Coverage

Report Scope Details
Market Size USD 2.70 billion by 2030
Growth Rate CAGR of 9.0% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Process, Product, Workflow, Application, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Lonza; Axol Biosciences Ltd.; Evotec; Hitachi Ltd.; Merck KGaA; REPROCELL Inc.; Fate Therapeutics; Thermo Fisher Scientific, Inc.; StemCellFactory III; Applied StemCell Inc.

Report Highlights

The manual iPSC production process segment dominated the global market in 2020 with a revenue share of 80.13%. The iPSC production process can be cost-effective and efficient by simply optimizing the manual steps routinely used to reprogram patient cells.

The automated iPSC production process is expected to register the fastest CAGR from 2021 to 2030. Increasing demand for reproducible large-scale stem cell and differentiated progeny production, with minimum variation, propels the demand for automation platforms.

Several of these initiatives plan to use automated systems to achieve their goal. For instance, various consortiums in Europe aim to develop iPSCs biobank for different diseases.

Cell culture was the dominant workflow segment in 2020 with a revenue share of more than 40% and is estimated to expand further at a steady CAGR over the forecast period. The studies of stem cell behavior and differentiation in development are complicated, expensive, and time-consuming, and thus, cell culture is a prominent workflow in generating iPSC. Traditional human-induced pluripotent stem cells culture technique requires the use of human or mouse fibroblast feeder layers, which is a time-consuming and labor-intensive process.

the reprogramming of iPSCs production market space has undergone various advancements in the past few years. The reprogramming of somatic cells into iPS cells has a high potential, enabling researchers to push forward groundbreaking research and discover the advanced generation of therapeutics.

the differentiation type is also expected to show significant growth in the coming years. Several companies are dedicated to providing different viable and cost-effective methods for iPSCs differentiation, which supports segment growth

The automated platforms segment is expected to register the fastest CAGR of 9.9% from 2021 to 2030. Automated platforms are known to produce more reliable iPSCs, minimizing human bias, while ensuring standardization of protocols.

The Instruments/devices accounted for the second-highest revenue share in 2020. The instruments/devices have the potential to help in iPSC generation by regulating the kinetics of reprogramming factor delivery. A substantial number of players are offering instruments/devices under this segment.

The drug development & discovery segment accounted for the largest revenue share of 45.90% of the global induced pluripotent stem cells generation market in 2020. iPSCs have broad applications in efficacy and safety evaluation during the drug development process.

iPSCs allow in vitro differentiation into various types of cells that constitute the organs and tissues. Currently, commercially usable iPSC-derived products include hepatocytes, cardiomyocytes, islet cells, vascular endothelial cells, and neurons, which are being studied to explain the mechanisms of human-specific adverse events and toxicity screening during drug exploration.

The regenerative medicine segment is expected to witness the fastest CAGR over the forecast period owing to the ability of iPSCs to propagate indefinitely. In addition, the development and launch of new platforms are contributing to the segment growth.

Biotechnology & pharmaceutical companies dominated the market with a revenue share of more than 60% in 2020. Acknowledging the profitable opportunities posed by the market, biotechnology companies are focused on initiating new product development to strengthen their market presence.

researchers have taken iPSCs from the lab to the clinics. iPSCs have been utilized in many clinical and research studies, including regenerative medicine, disease modeling, and drug toxicity/drug discovery studies. The utilization of iPSCs in regenerative medicine gives a great opportunity for the clinical translation of this technology.

North America dominated the market with a revenue share of more than 53% in 2020 The robust business model in the U.S. and Canada contributed to the market growth in the region. Moreover, organizations are investing in research programs related to iPSCs.

Europe is expected to witness steady growth over the forecast period. The development of the EBiSC accelerates the research activities about iPSCs in this region. The EBiSC aims to deliver disease-relevant, quality-controlled, research-grade iPS cell lines, data, and cell services.

Companies are entering into agreements for expanding their iPSC-derived therapies, which, in turn, will drive the research activities in the region. In June 2021, Neurophth Therapeutics formed a strategic partnership with Hopstem Biotechnology to develop human iPSC-derived therapies for the treatment of ocular diseases. Under

Key Players

  • Lonza
  • Axol Biosciences Ltd.
  • Evotec
  • Hitachi Ltd.
  • Merck KGaA
  • REPROCELL, Inc.
  • Fate Therapeutics
  • Thermo Fisher Scientific, Inc.
  • StemCellFactory III
  • Applied StemCell, Inc.

Market Segmentation

  • Process
    • Manual
    • Automated
  • Product
    • Instruments/Devices
    • Automated Platforms
    • Consumables & Kits
      • Media
      • Kits
      • Others
    • Services
  • Workflow
    • Reprogramming
    • Cell Culture
    • Cell Characterization/Analysis
    • Engineering
    • Others
  • Application
    • Drug Development and Discovery
    • Regenerative Medicine
    • Toxicology Studies
    • Others
  • End-use
    • Research & Academic Institutes
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & clinics
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38601

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Induced Pluripotent Stem Cells Production Market, By Process

7.1.  Induced Pluripotent Stem Cells Production Market, by Process, 2021-2030

7.1.1.    Manual

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Automated

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Induced Pluripotent Stem Cells Production Market, By Product

8.1.  Induced Pluripotent Stem Cells Production Market, by Product, 2021-2030

8.1.1.    Instruments/Devices

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Automated Platforms

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Consumables & Kits

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Services

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Induced Pluripotent Stem Cells Production Market, By Workflow

9.1.  Induced Pluripotent Stem Cells Production Market, by Workflow, 2021-2030

9.1.1.    Reprogramming

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cell Culture

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Cell Characterization/Analysis

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Engineering

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Induced Pluripotent Stem Cells Production Market, By Application

10.1.        Induced Pluripotent Stem Cells Production Market, by Application, 2021-2030

10.1.1.  Drug Development and Discovery

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Regenerative Medicine

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Toxicology Studies

10.1.3.1.      Market Revenue and Forecast (2017-2030)

10.1.4.  Others

10.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Induced Pluripotent Stem Cells Production Market, By End-use

11.1.        Induced Pluripotent Stem Cells Production Market, by End-use, 2021-2030

11.1.1.  Research & Academic Institutes

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Biotechnology & Pharmaceutical Companies

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  Hospitals & clinics

11.1.3.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Induced Pluripotent Stem Cells Production  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, by Process (2017-2030)

12.1.2.  Market Revenue and Forecast, by Product (2017-2030)

12.1.3.  Market Revenue and Forecast, by Workflow (2017-2030)

12.1.4.  Market Revenue and Forecast, by Application (2017-2030)

12.1.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, by Process (2017-2030)

12.1.6.2.      Market Revenue and Forecast, by Product (2017-2030)

12.1.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.1.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.1.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.1.7.  Rest of North America

12.1.7.1.      Market Revenue and Forecast, by Process (2017-2030)

12.1.7.2.      Market Revenue and Forecast, by Product (2017-2030)

12.1.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.1.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.1.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, by Process (2017-2030)

12.2.2.  Market Revenue and Forecast, by Product (2017-2030)

12.2.3.  Market Revenue and Forecast, by Workflow (2017-2030)

12.2.4.  Market Revenue and Forecast, by Application (2017-2030)

12.2.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, by Process (2017-2030)

12.2.6.2.      Market Revenue and Forecast, by Product (2017-2030)

12.2.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.2.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.7.  Germany

12.2.7.1.      Market Revenue and Forecast, by Process (2017-2030)

12.2.7.2.      Market Revenue and Forecast, by Product (2017-2030)

12.2.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.2.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.8.  France

12.2.8.1.      Market Revenue and Forecast, by Process (2017-2030)

12.2.8.2.      Market Revenue and Forecast, by Product (2017-2030)

12.2.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.2.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.9.  Rest of Europe

12.2.9.1.      Market Revenue and Forecast, by Process (2017-2030)

12.2.9.2.      Market Revenue and Forecast, by Product (2017-2030)

12.2.9.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.2.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, by Process (2017-2030)

12.3.2.  Market Revenue and Forecast, by Product (2017-2030)

12.3.3.  Market Revenue and Forecast, by Workflow (2017-2030)

12.3.4.  Market Revenue and Forecast, by Application (2017-2030)

12.3.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, by Process (2017-2030)

12.3.6.2.      Market Revenue and Forecast, by Product (2017-2030)

12.3.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.3.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.7.  China

12.3.7.1.      Market Revenue and Forecast, by Process (2017-2030)

12.3.7.2.      Market Revenue and Forecast, by Product (2017-2030)

12.3.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.3.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.8.  Japan

12.3.8.1.      Market Revenue and Forecast, by Process (2017-2030)

12.3.8.2.      Market Revenue and Forecast, by Product (2017-2030)

12.3.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.3.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.9.  Rest of APAC

12.3.9.1.      Market Revenue and Forecast, by Process (2017-2030)

12.3.9.2.      Market Revenue and Forecast, by Product (2017-2030)

12.3.9.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.3.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, by Process (2017-2030)

12.4.2.  Market Revenue and Forecast, by Product (2017-2030)

12.4.3.  Market Revenue and Forecast, by Workflow (2017-2030)

12.4.4.  Market Revenue and Forecast, by Application (2017-2030)

12.4.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, by Process (2017-2030)

12.4.6.2.      Market Revenue and Forecast, by Product (2017-2030)

12.4.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.4.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.7.  North Africa

12.4.7.1.      Market Revenue and Forecast, by Process (2017-2030)

12.4.7.2.      Market Revenue and Forecast, by Product (2017-2030)

12.4.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.4.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.8.  South Africa

12.4.8.1.      Market Revenue and Forecast, by Process (2017-2030)

12.4.8.2.      Market Revenue and Forecast, by Product (2017-2030)

12.4.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.4.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.9.  Rest of MEA

12.4.9.1.      Market Revenue and Forecast, by Process (2017-2030)

12.4.9.2.      Market Revenue and Forecast, by Product (2017-2030)

12.4.9.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.4.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, by Process (2017-2030)

12.5.2.  Market Revenue and Forecast, by Product (2017-2030)

12.5.3.  Market Revenue and Forecast, by Workflow (2017-2030)

12.5.4.  Market Revenue and Forecast, by Application (2017-2030)

12.5.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, by Process (2017-2030)

12.5.6.2.      Market Revenue and Forecast, by Product (2017-2030)

12.5.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.5.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.5.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.5.7.  Rest of LATAM

12.5.7.1.      Market Revenue and Forecast, by Process (2017-2030)

12.5.7.2.      Market Revenue and Forecast, by Product (2017-2030)

12.5.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

12.5.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.5.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 13.  Company Profiles

13.1.              Lonza

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Axol Biosciences Ltd.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Evotec

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Hitachi Ltd.

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              Merck KGaA

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              REPROCELL, Inc.

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Fate Therapeutics

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Thermo Fisher Scientific, Inc.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              StemCellFactory III

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Applied StemCell, Inc.

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

15.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38601

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button